An advanced allogeneic CD19‐CAR iNKT product co‐expressing IL‐15 and shRNAs against B2M/CD74 (to reduce HLA‐I/II expression) demonstrated efficacy in R/R non‐hodgkin lymphoma and acute lymphoblastic leukemia.163. This evidence concerns the gene CD74 and lymphoma.